Oklahoma’s case is scheduled to begin May 28 at a state courthouse in Norman. Judge Thad Balkman has repeatedly refused to delay the trial and has agreed to have it televised live every day, raising the prospect of nationwide coverage of grieving families and embarrassing internal company emails. Nearly 800 Oklahomans died of drug overdoses in 2017, about half of them from opioids.
“What happens there is going to set the standard for what happens after it,” said Abbe R. Gluck, a Yale Law School professor, who predicted that the outcome in Oklahoma could provide leverage to the victor in the larger federal case to follow.
Thirty-six states have filed cases in state courts, believing they will fare better in front of local juries that know the toll of addiction firsthand. The state cases have received far less attention than the mammoth case in Cleveland, where there are nearly 1,600 plaintiffs in an action known as multidistrict litigation, or MDL. If the trial holds to schedule, Oklahoma will be the first state to try a case in court.
The next few months will be critical to both cases.
Some believe the drug company defendants in Oklahoma — Purdue Pharma, Johnson & Johnson, Teva Pharmaceuticals, Actavis and others — will never risk a trial in that kind of venue, before a jury of Sooners who have seen the opioid epidemic’s impact on their communities.
“We feel confident in our case,” said Oklahoma Attorney General Mike Hunter, who filed the lawsuit in 2017. “We’d like a jury of Oklahomans to hear our evidence and determine the extent to which these companies should be held accountable for what’s happened in Oklahoma.”
The state contends that the drug manufacturers’ deceptive marketing of their products set off the epidemic and created a “public nuisance” that injured or endangered the health of Oklahoma citizens. The state could seek more than $1 billion from the companies, either in a settlement or at trial, according to people familiar with the case.
Oklahoma’s biggest target might be Janssen Pharmaceuticals, part of Johnson & Johnson. Janssen sells the Duragesic fentanyl patch and sold the opioid Nucynta until 2015.
Janssen said in a statement that “our actions in the marketing and promotion of these medicines were appropriate and responsible. The labels for our prescription opioid pain medicines provide information about their risks and benefits, and the allegations made against our company are baseless and unsubstantiated.”
Purdue said in a statement that it “continues to have active discussions with attorneys general, and is fully engaged with the multidistrict litigation process outlined by Judge Polster to help communities address the opioid crisis.” U.S. District Judge Dan Aaron Polster of the Northern District of Ohio is hearing the MDL case.
In Oklahoma, Purdue will argue that it controls a small share of the market for opioid drugs — about 2 percent to 3 percent. It claims its sales representatives and marketing initiatives are not responsible for deaths from illicit heroin and fentanyl, a powerful synthetic opioid manufactured overseas that is blamed for many opioid deaths in recent years.
Polster has aggressively pushed the parties in his courtroom toward a settlement of what some call the most complex litigation in U.S. history. The judge has said his goal is not just recompense for the costs of addressing addiction and death; he wants to abate the epidemic by providing money for treatment and other needs. More than 47,000 people died of opioid overdoses in 2017.
Settlement talks are continuing, but the attorneys missed Polster’s goal of reaching a unified agreement last year.
At the same time, Polster has set an October trial date for three bellwether cases — from the city of Cleveland and two Ohio counties — designed to determine how plaintiffs and defendants might fare before juries. Defendants include not just pharmaceutical manufacturers but opioid distributors, drugstore chains and pharmacy benefit managers.
State lawsuits like the one in Oklahoma could expose granular detail about the inner workings of the companies and their attitudes toward profits and the drug crisis. The cases already have revealed private Purdue emails that attorneys general say make the Sackler family — which owns the company — seem insatiably greedy and callous to the suffering opioid abuse has caused.
Perdue also has been fighting a lawsuit in a Massachusetts state court, proceedings that led to the release of previously secret documents in support of allegations that Purdue deceived patients and doctors to persuade them to take higher doses of its painkiller OxyContin more often and longer.
“Millions of dollars were not enough. They wanted billions,” the lawsuit alleges. “They cared more about money than about patients, or their employees, or the truth.”
Purdue has said the lawsuit unfairly vilifies “a single manufacturer whose medicines represent less than two percent of opioid pain prescriptions.”
In Utah, state Attorney General Sean D. Reyes last month filed an administrative action alleging that Purdue and two members of the Sackler family violated the Utah Consumer Sales Practices Act. In a statement, Reyes said an administrative proceeding allows the state to obtain a judgment and recoup penalties faster than a court proceeding.
Bradley Beckworth, one of the private attorneys hired to represent Oklahoma, said individual states are better positioned to take on the drug companies than the huge amalgam of parties involved in the federal litigation.
“With over a thousand competing interests, the MDL process could be a real slow train,” Beckworth said in an interview in the Oklahoma City office where he and other lawyers spend each week before returning to their homes in Austin. “In Norman, we have a court determined to start a trial May 28 with one focus: Oklahoma.”
The lawyers, who sleep on beds in their offices, are sifting through more than 50 million pages of documents obtained during the discovery process, Beckworth said. They have taken hundreds of depositions. Next month, they will add two members of the Sackler family to the total, he said.
A settlement is far from certain. In the landmark 1998 deal between 46 states and the four largest tobacco companies — the case most often compared to the pharmaceutical litigation — four early state settlements prompted talks between the companies and the rest of the states, said Richard Ausness, a professor at the University of Kentucky School of Law who tracks the cases.
Ultimately, the tobacco industry agreed to pay 46 states $206 billion over 25 years.
But in a comparable case, it took 16 trials, with drug company Merck winning 10, before the drugmaker agreed to settle with nearly 30,000 plaintiffs over the painkiller Vioxx. Merck eventually agreed in 2007 to pay the plaintiffs $4.85 billion for claims that the painkiller increased the risk of heart attacks and strokes. The company also withdrew Vioxx from the market.
In 2015, the state of Kentucky settled a case against Purdue for $24 million.
The current opioid cases are too complex, with too many actors, to make any predictions of how Oklahoma will affect the later cases, Ausness said.
“There are so many parties, and they’re so dug in, and I think the real litigation and the most important litigation is the MDL,” he said. “I would be willing to bet money it won’t end on May 28 — at least May 28, 2019. Maybe May 28, 2030.”
A serious concern among lawyers in the state and federal cases is the possibility that some companies might declare bankruptcy before plaintiffs collect potential settlements or awards.
Luke A. Barefoot
, a New York bankruptcy lawyer, said civil litigation against a company would halt as soon as it declares bankruptcy. It would be much more difficult for any plaintiff to secure funds in bankruptcy court proceedings. The possibility of a bankruptcy filing could be used for protection or leverage in negotiations about penalties, he said.
A bankruptcy filing also could delay the trials.
Should a major company in the lawsuit declare bankruptcy, Oklahoma law would allow the state to collect any damages from other defendants if it proves they are all liable.
Jeanne Whalen contributed to this report.